Camille E. Morgan , Casey A. Rimland , Griffin J. Bell , Min K. Kim , Tanner Hedrick , Ashley Marx , Brian Bramson , Heidi Swygard , Sonia Napravnik , John L. Schmitz , Shannon S. Carson , William A. Fischer , Joseph J. Eron , Cynthia L. Gay , Jonathan B. Parr
{"title":"Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic","authors":"Camille E. Morgan , Casey A. Rimland , Griffin J. Bell , Min K. Kim , Tanner Hedrick , Ashley Marx , Brian Bramson , Heidi Swygard , Sonia Napravnik , John L. Schmitz , Shannon S. Carson , William A. Fischer , Joseph J. Eron , Cynthia L. Gay , Jonathan B. Parr","doi":"10.1016/j.hjdsi.2021.100581","DOIUrl":null,"url":null,"abstract":"<div><p>The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty.</p></div>","PeriodicalId":29963,"journal":{"name":"Healthcare-The Journal of Delivery Science and Innovation","volume":"9 4","pages":"Article 100581"},"PeriodicalIF":2.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hjdsi.2021.100581","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare-The Journal of Delivery Science and Innovation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213076421000646","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 1
Abstract
The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty.
期刊介绍：
HealthCare: The Journal of Delivery Science and Innovation is a quarterly journal. The journal promotes cutting edge research on innovation in healthcare delivery, including improvements in systems, processes, management, and applied information technology.
The journal welcomes submissions of original research articles, case studies capturing "policy to practice" or "implementation of best practices", commentaries, and critical reviews of relevant novel programs and products. The scope of the journal includes topics directly related to delivering healthcare, such as:
● Care redesign
● Applied health IT
● Payment innovation
● Managerial innovation
● Quality improvement (QI) research
● New training and education models
● Comparative delivery innovation
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
